Structural Heart Procedures Market Analysis: Opportunities in TAVR, TMVR and Tricuspid Treatment

0
8

The Structural Heart Procedures Market was valued at about USD 13.20 billion in 2025 and USD 14.34 billion in 2026, and it is projected to reach USD 28.02 billion by 2034. That implies a CAGR of 8.72% from 2026 to 2034. Growth is being driven by a rising burden of valvular heart disease and a growing elderly population, both of which are increasing demand for these interventions worldwide. Structural heart disease treatment focuses on correcting problems in the heart’s valves, walls and chambers without open-heart surgery. Common procedures include transcatheter aortic valve replacement, mitral valve repair, left atrial appendage occlusion and septal defect closure.

Why Demand Keeps Rising

Aortic stenosis and mitral regurgitation need timely treatment, and cases are climbing. Citing the American Heart Association, the report notes that global heart valve disease in 2021 included 54.8 million cases of rheumatic heart disease, 13.3 million of calcific aortic valve disease and 15.5 million of degenerative mitral valve disease. Aging adds to the pressure. The World Health Organization expects the global population aged 60 and above to grow from 1 billion in 2020 to 2.1 billion in 2050. Older patients are more likely to develop valve problems through age-related wear and weakening of the heart muscle, so procedure volumes should keep rising.

Patient preference matters as well. Minimally invasive options mean shorter hospital stays, faster recovery and good clinical outcomes. Better catheterization techniques, higher healthcare spending, improved diagnosis rates and wider access to cardiac care all support this shift.

Procedure Segments

Transcatheter aortic valve replacement (TAVR) led in 2025 with nearly 62.40% of the market, supported by strong clinical outcomes, shorter recovery times and expanding approvals for broader patient groups. In October 2025, Medtronic launched the Stedi Extra Support Guidewire to improve procedural support for its TAVR systems.

Transcatheter mitral valve replacement (TMVR) is expected to grow fastest, at around 13.20% annually, as mitral valve disorders become more common and catheter-based repair gains acceptance among high-risk patients. In December 2025, Edwards Lifesciences received FDA clearance for the SAPIEN M3, the first transseptal transcatheter mitral valve replacement for severe mitral regurgitation patients who cannot have surgery.

Indications and End Users

Aortic stenosis was the leading indication in 2025, reflecting its high prevalence among older adults and the strong use of valve replacement. Tricuspid regurgitation is projected to grow fastest, at nearly 12.80% annually, as awareness of untreated valve disease increases and new transcatheter options emerge. Mitral regurgitation, atrial fibrillation and congenital heart defects are also key indications.

Hospitals dominated the end-user landscape with approximately 68.70% of the market. They have advanced imaging systems, skilled surgeons and hybrid operating rooms, and they remain the main centers for complex cases. Specialized cardiac centers are expected to grow fastest, driven by demand for focused cardiac care, faster treatment pathways and deep specialist expertise.

AI, Robotics and Outpatient Care

Technology is changing how these procedures are planned and performed. AI-based imaging helps clinicians understand anatomy, select devices and avoid planning errors. In March 2026, Medtronic announced that its AI-powered clinician alerts helped improve heart valve diagnosis and timely intervention. In November 2025, Philips introduced an AI-based imaging system designed to increase the precision and efficiency of transcatheter mitral valve repair. Robotic-assisted interventions are gaining attention for added precision, and a growing share of procedures are shifting to outpatient settings because of shorter recovery periods. These trends create openings for technology providers, device makers and hospitals.

Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/structural-heart-procedures-market

Regional Outlook

North America led in 2025 with nearly 41.60% of the market, thanks to advanced cardiac infrastructure, high healthcare spending and strong adoption of minimally invasive procedures. The US benefits from a large elderly population and a strong base of medical device companies. According to the US Census Bureau, the population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050.

Asia Pacific is expected to grow fastest as cardiovascular disease burden rises and access to advanced care improves in China, India, Japan and South Korea. In February 2026, Medanta Noida launched its structural heart programme after completing its first three TAVI procedures for severe aortic stenosis. Hospital investment and growing awareness of early treatment are also supporting demand.

Europe holds a considerable share, backed by strong healthcare facilities and wider use of catheter-based cardiac procedures. The OECD reports that cardiovascular disease causes one in three deaths in the EU, about 1.7 million in 2022, and affects roughly 62 million people. Germany, France and the UK are the largest markets.

Competitive Landscape

The Structural Heart Procedures Market is moderately concentrated. Leading companies include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, Johnson & Johnson MedTech, Meril Life Sciences, LivaNova, Artivion, JenaValve Technology, MicroPort Scientific, Venus Medtech and Peijia Medical. Competition centers on product innovation, clinical efficacy, regulatory clearance, physician training and pricing. Companies are broadening their transcatheter portfolios, adopting AI-powered imaging, partnering with hospitals and expanding geographically.

Challenges to Watch

Cost is the main barrier. Advanced devices, complex equipment and imaging technology make procedures expensive, and institutions in lower-income countries often lack reimbursement programs. That delays treatment and slows market penetration in price-sensitive regions. Lower device costs, broader reimbursement and better physician training will matter for wider access.

Conclusion

Structural Heart Procedures Market growth through 2034 will depend on how well the industry combines clinical innovation, affordability and access. Rising valve disease, an aging global population and patient demand for faster recovery will keep TAVR, TMVR and tricuspid interventions in focus. Manufacturers that keep improving device performance, support clinicians with AI-enabled imaging and expand into fast-growing regions such as Asia Pacific are best placed to benefit, while hospitals and specialized cardiac centers that invest in skilled teams and modern infrastructure will lead the delivery of care.

More Trending Latest Reports By Polaris Market Research:

Construction And Demolition Waste Market

Chocolate Market

Soy Protein Ingredients Market

Rail Composites Market

Chocolate Market

Cooling Fabrics Market

Specialty Enzymes Market

Automotive E-Compressor Market

Benign Prostatic Hyperplasia Surgical Treatment Market

Zoeken
Categorieën
Read More
Other
Spinal Fusion Devices Market Size, Share, and Growth Forecast : Key Trends and Segment Analysis
The Spinal Fusion Devices Market was valued at US$ 8.22 Billion in 2025 and is projected to reach...
By Sanket2921 2026-09-28 05:33:16 0 211
Other
Technical SEO in the AI Search Era: A 2026 Playbook for Higher Rankings
Technical SEO in the AI Search Era: A 2026 Playbook for Higher Rankings Search doesn't work the...
By thatwarellp 2026-09-01 05:47:10 0 644
Health
Disposable Intestinal Wash Bags Market Industry Outlook, Demand and Emerging Trends
Polaris Market Research today announced findings from its latest report, projecting the global...
By sakshi11 2026-10-02 14:52:17 0 248
Shopping
What Makes Stussy a Good Match for Modern Vintage Fashion?
Understanding the Appeal of Modern Vintage Fashion Modern vintage fashion combines the charm of...
By essentialhodie01 2026-10-14 06:41:27 0 246
Other
Platinum Based Cancer Drug Market Size to Reach USD 1.97 Billion by 2034 | CAGR 2.9% | Market Share, Growth, Forecast & Outlook
According to a report by Intel Market Research, the global Platinum Based Cancer Drug Market was...
By atharv2711 2026-09-15 12:04:46 0 183
AC Mingle https://acmingle.com